Charles J. Blijdorp

Charles J. Blijdorp

Auto-generated profile, based on publicly available information

Charles J. Blijdorp

Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2021 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
CBCharles J. Blijdorp
Charles J. Blijdorp
OTOmar A. Z. Tutakhel
Omar A. Z. Tutakhel
THThomas A. Hartjes
Thomas A. Hartjes
TBThierry P. P. van Den Bosch
Thierry P. P. van Den Bosch
MHMartijn H. van Heugten
Martijn H. van Heugten
EHEwout J. Hoorn
Ewout J. Hoorn
Significance Statement: Urinary extracellular vesicles (uEVs) are a promising noninvasive source of kidney biomarkers, but the optimal approaches for normalization, quantification, and characterization in spot urines are unclear. To address the hypothesis that urine creatinine can be used as a normalization variable, urine particles were quantified in dilute and concentrated urines (water deprivation–loading study) and randomly from healthy subjects and patients with kidney disease. In these various settings, urine creatinine was highly correlated with particle counts, suggesting it can be used as a normalization variable. Additional findings relevant for future uEV studies include interference of Tamm-Horsfall protein with nanoparticle tracking analysis, excretion of larger uEVs in dilute urine, and the ability to treat uEVs with detergent to enhance intracellular epitope recognition. Background: Urinary extracellular vesicles (uEVs) are a promising source for biomarker discovery, but optimal approaches for normalization, quantification, and characterization in spot urines are unclear. Methods: Urine samples were analyzed in a water-loading study, from healthy subjects and patients with kidney disease. Urine particles were quantified in whole urine using nanoparticle tracking analysis (NTA), time-resolved fluorescence immunoassay (TR-FIA), and EVQuant, a novel method quantifying particles via gel immobilization. Results: Urine particle and creatinine concentrations were highly correlated in the water-loading study (R 2 0.96) and in random spot urines from healthy subjects (R 2 0.47–0.95) and patients (R 2 0.41–0.81). Water loading reduced aquaporin-2 but increased Tamm-Horsfall protein (THP) and particle detection by NTA. This finding was attributed to hypotonicity increasing uEV size (more EVs reach the NTA size detection limit) and reducing THP polymerization. Adding THP to urine also significantly increased particle count by NTA. In both fluorescence NTA and EVQuant, adding 0.01% SDS maintained uEV integrity and increased aquaporin-2 detection. Comparison of intracellular- and extracellular-epitope antibodies suggested the presence of reverse topology uEVs. The exosome markers CD9 and CD63 colocalized and immunoprecipitated selectively with distal nephron markers. Conclusions uEV concentration is highly correlated with urine creatinine, potentially replacing the need for uEV quantification to normalize spot urines. Additional findings relevant for future uEV studies in whole urine include the interference of THP with NTA, excretion of larger uEVs in dilute urine, the ability to use detergent to increase intracellular-epitope recognition in uEVs, and CD9 or CD63 capture of nephron segment–specific EVs.

22 January 2022 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
PDF file
CBCharles J. Blijdorp
Charles J. Blijdorp
THThomas A. Hartjes
Thomas A. Hartjes
KWKuang‐Yu Wei
Kuang‐Yu Wei
MHMartijn H. van Heugten
Martijn H. van Heugten
DBDominique M. Bovée
Dominique M. Bovée
EHEwout J. Hoorn
Ewout J. Hoorn
Urinary extracellular vesicles (uEVs) are emerging as non‐invasive biomarkers for various kidney diseases, but it is unknown how differences in nephron mass impact uEV excretion. To address this, uEV excretion was measured before and after human kidney donor nephrectomy and rat nephrectomy. In male and female donors, uEVs were quantified in cell‐free spot and 24‐h urine samples using nanoparticle tracking analysis (NTA), EVQuant, and CD9‐time‐resolved fluorescence immunoassay. Female donors had significantly lower total kidney volume (TKV) and excreted 49% fewer uEVs than male donors. uEV excretion correlated positively with estimated glomerular filtration rate (eGFR), creatinine clearance, and TKV (R's between 0.6 and 0.7). uEV excretion rate could also be predicted from spot urines after multiplying spot uEV/creatinine by 24‐h urine creatinine. Donor nephrectomy reduced eGFR by 36% ± 10%, but the excretion of uEVs by only 16% (CD9+ uEVs ‐37%, CD9‐ uEVs no decrease). Donor nephrectomy increased the podocyte marker WT‐1 and the proximal tubule markers NHE3, NaPi‐IIa, and cubilin in uEVs two‐ to four‐fold when correcting for the nephrectomy. In rats, the changes in GFR and kidney weight correlated with the changes in uEV excretion rate (R = 0.46 and 0.60, P < 0.01). Furthermore, the estimated degree of hypertrophy matched the change in uEV excretion rate (1.4‐ to 1.5‐fold after uninephrectomy and four‐fold after 5/6th nephrectomy). Taken together, our data show that uEV excretion depends on nephron mass, and that nephrectomy reduces uEV excretion less than expected based on nephron loss due to compensatory hypertrophy. The major implication of our findings is that a measure for nephron mass or uEV excretion rate should be included when comparing uEV biomarkers between individuals.

11 December 2023 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
MHMartijn H. van Heugten
Martijn H. van Heugten
CBCharles J. Blijdorp
Charles J. Blijdorp
SASita Arjune
Sita Arjune
HWHester van Willigenburg
Hester van Willigenburg
KBKarel Bezstarosti
Karel Bezstarosti
EHEwout J. Hoorn
Ewout J. Hoorn
Significance Statement: There is an unmet need for biomarkers of disease progression in autosomal dominant polycystic kidney disease (ADPKD). This study investigated urinary extracellular vesicles (uEVs) as a source of such biomarkers. Proteomic analysis of uEVs identified matrix metalloproteinase 7 (MMP-7) as a biomarker predictive of rapid disease progression. In validation studies, MMP-7 was predictive in uEVs but not in whole urine, possibly because uEVs are primarily secreted by tubular epithelial cells. Indeed, single-nucleus RNA sequencing showed that MMP-7 was especially increased in proximal tubule and thick ascending limb cells, which were further characterized by a profibrotic phenotype. Together, these data suggest that MMP-7 is a biologically plausible and promising uEV biomarker for rapid disease progression in ADPKD. Background: In ADPKD, there is an unmet need for early markers of rapid disease progression to facilitate counseling and selection for kidney-protective therapy. Our aim was to identify markers for rapid disease progression in uEVs. Methods: Six paired case–control groups (n=10–59/group) of cases with rapid disease progression and controls with stable disease were formed from two independent ADPKD cohorts, with matching by age, sex, total kidney volume, and genetic variant. Candidate uEV biomarkers were identified by mass spectrometry and further analyzed using immunoblotting and an ELISA. Single-nucleus RNA sequencing of healthy and ADPKD tissue was used to identify the cellular origin of the uEV biomarker. Results: In the discovery proteomics experiments, the protein abundance of MMP-7 was significantly higher in uEVs of patients with rapid disease progression compared with stable disease. In the validation groups, a significant >2-fold increase in uEV-MMP-7 in patients with rapid disease progression was confirmed using immunoblotting. By contrast, no significant difference in MMP-7 was found in whole urine using ELISA. Compared with healthy kidney tissue, ADPKD tissue had significantly higher MMP-7 expression in proximal tubule and thick ascending limb cells with a profibrotic phenotype. Conclusions: Among patients with ADPKD, rapid disease progressors have higher uEV-associated MMP-7. Our findings also suggest that MMP-7 is a biologically plausible biomarker for more rapid disease progression.

1 March 2022 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
CBCharles J. Blijdorp
Charles J. Blijdorp
DBDylan Burger
Dylan Burger
ALAlicia Llorente
Alicia Llorente
EMElena S. Martens-Uzunova
Elena S. Martens-Uzunova
UEUta Erdbrügger
Uta Erdbrügger

18 December 2022 in Kidney360
Verified
Journal Article
Closed access
PDF file
UEUta Erdbrügger
Uta Erdbrügger
EHEwout J. Hoorn
Ewout J. Hoorn
TLThu Le
Thu Le
CBCharles J. Blijdorp
Charles J. Blijdorp
DBDylan Burger
Dylan Burger
Extracellular vesicles (EVs) are evolving as novel cell mediators, biomarkers, and therapeutic targets in kidney health and disease. They are naturally derived from cells both within and outside the kidney and carry cargo which mirrors the state of the parent cell. Thus, they are potentially more sensitive and disease-specific as biomarkers and messengers in various kidney diseases. Beside their role as novel communicators within the nephron, they likely communicate between different organs affected by various kidney diseases. Study of urinary EVs (uEVs) can help to fill current knowledge gaps in kidney diseases. However, separation and characterization are challenged by their heterogeneity in size, shape, and cargo. Fortunately, more sensitive and direct EV measuring tools are in development. Many clinical syndromes in nephrology from acute to chronic kidney and glomerular to tubular diseases have been studied. Yet, validation of biomarkers in larger cohorts is warranted and simpler tools are needed. Translation from in vitro to in vivo studies is also urgently needed. The therapeutic role of uEVs in kidney diseases has been studied extensively in rodent models of AKI. On the basis of the current exponential growth of EV research, the field of EV diagnostics and therapeutics is moving forward.

23 December 2024 in Kidney360
Verified
Journal Article
Open access
FGFrank Geurts
Frank Geurts
MHMartijn H. van Heugten
Martijn H. van Heugten
CBCharles J. Blijdorp
Charles J. Blijdorp
RFRobert Fenton Fenton
Robert Fenton Fenton
LCLayal Chaker
Layal Chaker
EHEwout J. Hoorn
Ewout J. Hoorn
Key Points: Donor nephrectomy reduced urinary EGF (uEGF) by half and correlated with the reduction in kidney volume, suggesting that uEGF reflects tubular mass. In the general population, lower uEGF/creatinine was associated with lower eGFR, lower serum magnesium, and higher BP. Lower uEGF/creatinine, was associated with incident CKD, and this association was stronger in people without hypertension. Background: EGF is expressed in the distal tubule and secreted in urine (urinary EGF [uEGF]) after cleavage of membrane-bound pro-EGF. Lower uEGF is associated with kidney disease progression. EGF also plays a role in the regulation of serum magnesium and BP, but whether uEGF is associated with these parameters is unknown. We hypothesized that uEGF is a distal tubule marker associated with serum magnesium, BP, and kidney outcomes. Methods: We first used a cohort of kidney donors (N=20) and measured uEGF to analyze the association with tubular mass and pro-EGF in urinary extracellular vesicles as proxy for tubular expression. Next, we measured uEGF in a population-based cohort (N=2382) to investigate the associations with serum magnesium, hypertension, and kidney outcomes (incident eGFR <60 or <45 ml/min per 1.73 m2, 40% loss of eGFR, or kidney failure). Results: Kidney donation decreased eGFR from 86 to 54 ml/min per 1.73 m2 (36% reduction; 95% confidence interval [CI], 31% to 42%), uEGF from 28 to 14 µg/24 hours (49% reduction; 95% CI, 42% to 55%), and pro-EGF by 29% (95% CI, 12% to 45%). The decrease in uEGF correlated with the decrease in kidney volume. In the population cohort, lower uEGF was significantly associated with hypertension and lower serum magnesium. The association between uEGF and serum magnesium was stronger in participants with lower eGFR, hypertension, and diuretic use. Lower uEGF at baseline was also associated with worse kidney outcomes, and this association was stronger for normotensive participants. Conclusions: uEGF is a marker of distal tubular mass that is not only associated with kidney disease progression, but also with serum magnesium and BP. Future studies should address whether normotensive people with low uEGF excretion represent a group that may benefit from kidney-protective treatment.